There are 1076 resources available
688P - The efficacy of first-line chemotherapy combined with immunotherapy or anti-angiogenic therapy for advanced KRAS-mutant non-small cell lung cancer
Presenter: Huiping Qiang
Session: Poster Display session
Resources:
Abstract
689P - Patterns of disease progression and efficacy of local ablative therapy among patients with metastatic EGFR-mutation positive non-small cell lung cancer treated with first-line osimertinib
Presenter: Chih Chi Chen
Session: Poster Display session
Resources:
Abstract
690P - Clinical outcomes of patients with advanced EGFR mutation positive (EGFRm) non-small cell lung cancer (NSCLC) with MET amplification (METamp) after osimertinib resistance: A multicentre retrospective study
Presenter: Olivia Han Chen
Session: Poster Display session
Resources:
Abstract
691P - Mechanisms of acquired resistance to first-line (1L) osimertinib in EGFR-mutated (EGFRm) advanced NSCLC: Results from a prospective, multi-center, real-world study in China (FLOURISH study)
Presenter: Jing Zheng
Session: Poster Display session
Resources:
Abstract
692P - Landscape of co-occurring OncoKB tier 1/2 alterations in EGFR-mutated lung adenocarcinoma (LUAD) harboring common driver alterations using circulating tumor DNA (ctDNA) next generation sequencing (NGS) in Asia and the Middle East (AME)
Presenter: Shaheenah Dawood
Session: Poster Display session
Resources:
Abstract
693P - Treatment comparison of amivantamab vs. real-world therapies among patients with NSCLC harboring EGFR Exon 20 insertion mutations: An external control analysis (ECA) using NTUH NSCLC dataset in Taiwan
Presenter: Jenn-Yu Wu
Session: Poster Display session
Resources:
Abstract
694P - Chemoimmunotherapy versus pembrolizumab as a first-line treatment for patients with advanced non-small cell lung cancer and high PD-L1 expression: Focus on the role of performance status
Presenter: Tadaaki Yamada
Session: Poster Display session
Resources:
Abstract
695P - Second-line envafolimab and beyond in locally advanced or metastatic non-small cell lung cancer
Presenter: Maojing Guan
Session: Poster Display session
Resources:
Abstract
696P - Impact of local therapy on survival in patients with brain metastases from non-small cell lung cancer (NSCLC): A real-world cohort study
Presenter: Lige Wu
Session: Poster Display session
Resources:
Abstract
697P - Aumolertinib plus anlotinib as first-line treatment for EGFR mutant non-small cell lung cancer: A phase II trial (ALWAYS)
Presenter: Hua Lin Chen
Session: Poster Display session
Resources:
Abstract